Vowst is approved to prevent recurrences of C. difficile in people 18 and older following antibacterial treatment, according to an April 26 news release from the agency. Four capsules are taken once per day for three consecutive days, and they contain live bacteria manufactured from human fecal matter.
It is the latest drug to be approved for recurrent C. difficile. In November, the FDA approved the first fecal transplant therapy, Rebyota, for people with ongoing C. difficile. On April 12, five medical associations published guidelines on fighting C. difficile infections, which included a call to adopt antimicrobial stewardship programs.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
